Wai Yuen Tong Medicine Holdings Limited Statistics
Want to see HK:0897 full AI Analyst Report?
Wai Yuen Tong Medicine Holdings Limited (0897) Stock Statistics & Valuation Metrics
Total Valuation
Wai Yuen Tong Medicine Holdings Limited has a market cap or net worth of HKD 406.75M. The enterprise value is HKD 560.58M.
- Market Cap
- HKD 406.75M
- Enterprise Value
- HKD 560.58M
Share Statistics
Wai Yuen Tong Medicine Holdings Limited has 1,114,382,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,114,382,900
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Wai Yuen Tong Medicine Holdings Limited’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is -1.16%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- -1.16%
- Return on Capital Employed (ROCE)
- -0.01
- Revenue Per Employee
- 989.06K
- Profits Per Employee
- 5,777.135
- Employee Count
- 691
- Asset Turnover
- 0.42
- Inventory Turnover
- 1.42
Valuation Ratios
The current PE Ratio of Wai Yuen Tong Medicine Holdings Limited is 101.39. Wai Yuen Tong Medicine Holdings Limited’s PEG ratio is -0.19.
- PE Ratio
- 101.39
- PS Ratio
- 0.60
- PB Ratio
- 0.34
- Price to FCF
- 4.72
- Price to Operating Cash Flow
- 4.06
- PEG Ratio
- -0.19
Income Statement
In the last 12 months, Wai Yuen Tong Medicine Holdings Limited had revenue of 683.44M and earned 3.99M in profits. Earnings per share was 0.00.
- Revenue
- 683.44M
- Gross Profit
- 361.93M
- Operating Income
- -17.10M
- Pretax Income
- 3.63M
- Net Income
- 3.99M
- EBITDA
- 67.05M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 99.70M and capital expenditures -13.49M, giving a free cash flow of 86.21M billion.
- Operating Cash Flow
- 99.70M
- Free Cash Flow
- 86.21M
- Free Cash Flow per Share
- 0.08
Dividends & Yields
Wai Yuen Tong Medicine Holdings Limited pays an annual dividend of HKD 0.03, resulting in a dividend yield of ―
- Dividend Per Share
- HKD 0.03
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 21.19%
- Earnings Yield
- 0.99%
Stock Price Statistics
- Beta
- 0.68
- 52-Week Price Change
- -19.78%
- 50-Day Moving Average
- 0.36
- 200-Day Moving Average
- 0.33
- Relative Strength Index (RSI)
- 49.95
- Average Volume (3m)
- 667.09K
Important Dates
Wai Yuen Tong Medicine Holdings Limited upcoming earnings date is Dec 01, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jun 25, 2026
- Next Earnings Date
- Dec 01, 2026
- Ex-Dividend Date
- Aug 22, 2024
Financial Position
Wai Yuen Tong Medicine Holdings Limited as a current ratio of 1.40, with Debt / Equity ratio of 23.63%
- Current Ratio
- 1.40
- Quick Ratio
- 0.87
- Debt to Market Cap
- 0.75
- Net Debt to EBITDA
- 2.18
- Interest Coverage Ratio
- -0.97
Taxes
In the past 12 months, Wai Yuen Tong Medicine Holdings Limited has paid -445.00K in taxes.
- Income Tax
- -445.00K
- Effective Tax Rate
- -0.12
Enterprise Valuation
Wai Yuen Tong Medicine Holdings Limited EV to EBITDA ratio is 8.13, with an EV/FCF ratio of 6.41.
- EV to Sales
- 0.81
- EV to EBITDA
- 8.13
- EV to Free Cash Flow
- 6.41
- EV to Operating Cash Flow
- 5.54
Balance Sheet
Wai Yuen Tong Medicine Holdings Limited has HKD 147.44M in cash and marketable securities with HKD 279.29M in debt, giving a net cash position of -HKD 131.85M billion.
- Cash & Marketable Securities
- HKD 147.44M
- Total Debt
- HKD 279.29M
- Net Cash
- -HKD 131.85M
- Net Cash Per Share
- -HKD 0.12
- Tangible Book Value Per Share
- HKD 1.06
Margins
Gross margin is 52.96%, with operating margin of -2.36%, and net profit margin of 0.58%.
- Gross Margin
- 52.96%
- Operating Margin
- -2.36%
- Pretax Margin
- 0.53%
- Net Profit Margin
- 0.58%
- EBITDA Margin
- 9.95%
- EBIT Margin
- -2.36%
Analyst Forecast
The average price target for Wai Yuen Tong Medicine Holdings Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -8.30%
- EPS Growth Forecast
- -44.44%
Scores
- Smart Score
- 7
- AI Score
- 53

